Join to View Full Profile
300 George St, New HavenSuite 120New Haven, CT 06520
Fax+1 203-785-5792
Dr. Pusztai is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of Texas Health Science Center at HoustonFellowship, Hematology and Medical Oncology, 1996 - 1999
Rochester Regional Health/Unity Hospital (Rochester)Residency, Internal Medicine, 1992 - 1996
Semmelweis UniversityClass of 1986
Certifications & Licensure
TX State Medical License 1997 - 2027
CT State Medical License 2012 - 2025
American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
- Fellow (FACP) American College of Physicians, 2003
Clinical Trials
- Safety, Efficacy and Pharmacokinetic Between Capecitabine and Exisulind in Metastatic Breast Cancer Patients Start of enrollment: 2001 Jan 01
- Vinorelbine With or Without Trastuzumab in Treating Women With Progressive Metastatic Breast Cancer Start of enrollment: 2004 Dec 01
- Randomized Clinical Trial to Evaluate the Predictive Accuracy of a Gene Expression for Stage I-II Breast Cancer Start of enrollment: 2003 Sep 01
- Join now to see all
Publications & Presentations
PubMed
- 1 citationsDevelopment and Validation of the RSClinN+ Tool to Predict Prognosis and Chemotherapy Benefit for Hormone Receptor-Positive, Node-Positive Breast Cancer.Lajos Pusztai, Jess R Hoag, Kathy S Albain, William E Barlow, Salomon M Stemmer
Journal of Clinical Oncology. 2025-03-10 - Determinants of response and molecular dynamics in HER2+ER+ breast cancers from the NA-PHER2 trial receiving HER2-targeted and endocrine therapies.Maurizio Callari, Matteo Dugo, Marco Barreca, Balázs Győrffy, Barbara Galbardi
Nature Communications. 2025-03-04 - A pooled analysis evaluating prognostic significance of Residual Cancer Burden in invasive lobular breast cancer.Rita A Mukhtar, Soumya Gottipati, Christina Yau, Sara López-Tarruella, Helena Earl
NPJ Breast Cancer. 2025-02-13
Journal Articles
- Cost-Effectiveness of Neoadjuvant-Adjuvant Treatment Strategies for Women with ERBB2 (HER2)–Positive Breast CancerLajos Pusztai, MD, JAMA Network Open
- Association of T-cell Receptor Repertoire Use with Response to Combined Trastuzumab-Lapatinib Treatment of HER2-Positive Breast CancerSecondary Analysis of the NeoALTT...Lajos Pusztai, Jose Baselga, JAMA
Lectures
- Durvalumab (MEDI4736) concurrent with nab-paclitaxel and dose dense doxorubicin cyclophosphamide (ddAC) as neoadjuvant therapy for triple negative breast cancer (TNBC).2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
- Why Do We Care About Molecular Evolution in Breast Cancer?2018 ASCO Annual Meeting - Chicago, Illinois - 06/1/2018
- 2013 Breast Cancer Symposium,American Society of Breast Surgeons, San Francisco, California - 9/7/2013
Press Mentions
Cryotherapy for Chemotherapy Neuropathy: Does It Work?March 14th, 2025- RSClin Tool N+ Enhances Breast Cancer Risk EstimatesJanuary 23rd, 2025
- RSClin® Tool N+ Enhances Accuracy in Recurrence Risk Estimation and Chemotherapy Benefit for Node-Positive Breast CancerJanuary 23rd, 2025
- Join now to see all
Grant Support
- Serum biomarkers to predict immune related adverse events and benefit from single agent pembrolizumab therapy in early stage triple negative breast cancerARIZONA STATE UNIVERSITY-TEMPE CAMPUS2023–2028
Professional Memberships
- Member
- Fellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
